Literature DB >> 21824921

Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro.

Hiroshi Watanabe1, Tao Yang, Dina Myers Stroud, John S Lowe, Louise Harris, Thomas C Atack, Dao W Wang, Susan B Hipkens, Brenda Leake, Lynn Hall, Sabina Kupershmidt, Nagesh Chopra, Mark A Magnuson, Naohito Tanabe, Björn C Knollmann, Alfred L George, Dan M Roden.   

Abstract

BACKGROUND: The D1275N SCN5A mutation has been associated with a range of unusual phenotypes, including conduction disease and dilated cardiomyopathy, as well as atrial and ventricular tachyarrhythmias. However, when D1275N is studied in heterologous expression systems, most studies show near-normal sodium channel function. Thus, the relationship of the variant to the clinical phenotypes remains uncertain. METHODS AND
RESULTS: We identified D1275N in a patient with atrial flutter, atrial standstill, conduction disease, and sinus node dysfunction. There was no major difference in biophysical properties between wild-type and D1275N channels expressed in Chinese hamster ovary cells or tsA201 cells in the absence or presence of β1 subunits. To determine D1275N function in vivo, the Scn5a locus was modified to knock out the mouse gene, and the full-length wild-type (H) or D1275N (DN) human SCN5A cDNAs were then inserted at the modified locus by recombinase mediated cassette exchange. Mice carrying the DN allele displayed slow conduction, heart block, atrial fibrillation, ventricular tachycardia, and a dilated cardiomyopathy phenotype, with no significant fibrosis or myocyte disarray on histological examination. The DN allele conferred gene-dose-dependent increases in SCN5A mRNA abundance but reduced sodium channel protein abundance and peak sodium current amplitudes (H/H, 41.0±2.9 pA/pF at -30 mV; DN/H, 19.2±3.1 pA/pF, P<0.001 vs. H/H; DN/DN, 9.3±1.1 pA/pF, P<0.001 versus H/H).
CONCLUSIONS: Although D1275N produces near-normal currents in multiple heterologous expression experiments, our data establish this variant as a pathological mutation that generates conduction slowing, arrhythmias, and a dilated cardiomyopathy phenotype by reducing cardiac sodium current.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824921      PMCID: PMC3297976          DOI: 10.1161/CIRCULATIONAHA.110.987248

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  48 in total

1.  Cardiac conduction defects associate with mutations in SCN5A.

Authors:  J J Schott; C Alshinawi; F Kyndt; V Probst; T M Hoorntje; M Hulsbeek; A A Wilde; D Escande; M M Mannens; H Le Marec
Journal:  Nat Genet       Date:  1999-09       Impact factor: 38.330

2.  Strategies for the use of site-specific recombinases in genome engineering.

Authors:  Julie R Jones; Kathy D Shelton; Mark A Magnuson
Journal:  Methods Mol Med       Date:  2005

3.  Mouse model of SCN5A-linked hereditary Lenègre's disease: age-related conduction slowing and myocardial fibrosis.

Authors:  Anne Royer; Toon A B van Veen; Sabrina Le Bouter; Céline Marionneau; Violaine Griol-Charhbili; Anne-Laure Léoni; Marja Steenman; Harold V M van Rijen; Sophie Demolombe; Catharine A Goddard; Christine Richer; Brigitte Escoubet; Thérèse Jarry-Guichard; William H Colledge; Daniel Gros; Jacques M T de Bakker; Andrew A Grace; Denis Escande; Flavien Charpentier
Journal:  Circulation       Date:  2005-04-04       Impact factor: 29.690

4.  Multiple mechanisms of Na+ channel--linked long-QT syndrome.

Authors:  R Dumaine; Q Wang; M T Keating; H A Hartmann; P J Schwartz; A M Brown; G E Kirsch
Journal:  Circ Res       Date:  1996-05       Impact factor: 17.367

5.  Sodium channel mutations and susceptibility to heart failure and atrial fibrillation.

Authors:  Timothy M Olson; Virginia V Michels; Jeffrey D Ballew; Sandra P Reyna; Margaret L Karst; Kathleen J Herron; Steven C Horton; Richard J Rodeheffer; Jeffrey L Anderson
Journal:  JAMA       Date:  2005-01-26       Impact factor: 56.272

6.  Measurement of heart rate and Q-T interval in the conscious mouse.

Authors:  G F Mitchell; A Jeron; G Koren
Journal:  Am J Physiol       Date:  1998-03

Review 7.  Sodium channels as macromolecular complexes: implications for inherited arrhythmia syndromes.

Authors:  L S Meadows; L L Isom
Journal:  Cardiovasc Res       Date:  2005-08-15       Impact factor: 10.787

8.  Genetic basis and molecular mechanism for idiopathic ventricular fibrillation.

Authors:  Q Chen; G E Kirsch; D Zhang; R Brugada; J Brugada; P Brugada; D Potenza; A Moya; M Borggrefe; G Breithardt; R Ortiz-Lopez; Z Wang; C Antzelevitch; R E O'Brien; E Schulze-Bahr; M T Keating; J A Towbin; Q Wang
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

9.  Molecular mechanism for an inherited cardiac arrhythmia.

Authors:  P B Bennett; K Yazawa; N Makita; A L George
Journal:  Nature       Date:  1995-08-24       Impact factor: 49.962

10.  Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes.

Authors:  Peter J Mohler; Ilaria Rivolta; Carlo Napolitano; Guy LeMaillet; Stephen Lambert; Silvia G Priori; Vann Bennett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-03       Impact factor: 11.205

View more
  51 in total

1.  Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

2.  Repolarization recipes for atrial fibrillation: beyond single channel variants.

Authors:  Dawood Darbar; Babar Parvez; Robert Abraham
Journal:  J Am Coll Cardiol       Date:  2012-03-13       Impact factor: 24.094

3.  Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic.

Authors:  Tao Yang; Thomas C Atack; Dina Myers Stroud; Wei Zhang; Lynn Hall; Dan M Roden
Journal:  Circ Res       Date:  2012-06-20       Impact factor: 17.367

4.  Forever young: induced pluripotent stem cells as models of inherited arrhythmias.

Authors:  David S Park; Glenn I Fishman
Journal:  Circulation       Date:  2012-05-30       Impact factor: 29.690

5.  Azithromycin Causes a Novel Proarrhythmic Syndrome.

Authors:  Zhenjiang Yang; Joseph K Prinsen; Kevin R Bersell; Wangzhen Shen; Liudmila Yermalitskaya; Tatiana Sidorova; Paula B Luis; Lynn Hall; Wei Zhang; Liping Du; Ginger Milne; Patrick Tucker; Alfred L George; Courtney M Campbell; Robert A Pickett; Christian M Shaffer; Nagesh Chopra; Tao Yang; Bjorn C Knollmann; Dan M Roden; Katherine T Murray
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-04

6.  Enhanced Classification of Brugada Syndrome-Associated and Long-QT Syndrome-Associated Genetic Variants in the SCN5A-Encoded Na(v)1.5 Cardiac Sodium Channel.

Authors:  Jamie D Kapplinger; John R Giudicessi; Dan Ye; David J Tester; Thomas E Callis; Carmen R Valdivia; Jonathan C Makielski; Arthur A Wilde; Michael J Ackerman
Journal:  Circ Cardiovasc Genet       Date:  2015-04-22

Review 7.  The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?

Authors:  Dawood Darbar
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 8.  Genetics of atrial fibrillation: from families to genomes.

Authors:  Ingrid E Christophersen; Patrick T Ellinor
Journal:  J Hum Genet       Date:  2015-05-21       Impact factor: 3.172

9.  Atrial Fibrillation and SCN5A Variants.

Authors:  Eleonora Savio-Galimberti; Dawood Darbar
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

10.  MOG1 rescues defective trafficking of Na(v)1.5 mutations in Brugada syndrome and sick sinus syndrome.

Authors:  Susmita Chakrabarti; Xiaofen Wu; Zhaogang Yang; Ling Wu; Sandro L Yong; Cuntai Zhang; Keli Hu; Qing K Wang; Qiuyun Chen
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.